Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer's (SITC) 38th Annual MeetingGlobeNewsWire • 09/27/23
Xilio Therapeutics Announces Promotion of Katarina Luptakova, M.D., to Chief Medical Officer and Scott Coleman, Ph.D.GlobeNewsWire • 09/05/23
Xilio Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare ConferenceGlobeNewsWire • 09/05/23
Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2023 Financial ResultsGlobeNewsWire • 08/14/23
Xilio Therapeutics Announces Promotion of Chris Frankenfield to Chief Operating OfficerGlobeNewsWire • 08/03/23
Xilio Therapeutics Announces Preliminary Clinical Data from Phase 1 Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Patients with Advanced Solid TumorsGlobeNewsWire • 05/25/23
Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2023 Financial ResultsGlobeNewsWire • 05/09/23
Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 04/03/23
Xilio Therapeutics Announces Pipeline and Business Updates for the Fourth Quarter and Full Year 2022 Financial ResultsGlobeNewsWire • 03/02/23
Xilio Therapeutics to Present at the Citi 2023 Virtual Oncology Leadership SummitGlobeNewsWire • 02/16/23
Xilio Therapeutics to Present at the Guggenheim Healthcare Talks Oncology DayGlobeNewsWire • 02/02/23
Xilio Therapeutics to Host Live Virtual Program Spotlighting XTX301, a Tumor-Activated IL-12GlobeNewsWire • 11/23/22
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2022 Financial ResultsGlobeNewsWire • 11/09/22
Xilio Therapeutics to Present at Guggenheim Nantucket Therapeutics ConferenceGlobeNewsWire • 09/22/22
Xilio Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare ConferenceGlobeNewsWire • 09/06/22
Xilio Therapeutics Announces Encouraging Preliminary Phase 1 Dose-Escalation Data for XTX101, a Tumor-Selective Anti-CTLA-4, and Reports Pipeline and Business Updates and Second Quarter 2022 Financial ResultsGlobeNewsWire • 08/09/22
Xilio Therapeutics to Present at the H.C. Wainwright Global Investment ConferenceGlobeNewsWire • 05/18/22
Xilio Therapeutics Reports Pipeline and Business Highlights and First Quarter 2022 Financial ResultsGlobeNewsWire • 05/12/22
Xilio Therapeutics to Present at the 21st Annual Needham Virtual Healthcare ConferenceGlobeNewsWire • 04/07/22
Xilio Therapeutics Reports Pipeline and Business Progress and Fourth Quarter and Full Year 2021 Financial ResultsGlobeNewsWire • 03/01/22
Xilio Therapeutics to Participate in the Cowen 42nd Annual Healthcare ConferenceGlobeNewsWire • 02/28/22